Maintenance therapy for added bone mass or how to keep the profit after withdrawal of therapy of osteopenia.
Maintenance therapy for added bone mass or how to keep the profit after withdrawal of therapy of osteopenia.
复制标题
增加骨量的维持治疗或如何在骨质减少治疗停止后保持利润。
DOI：
10.1016/8756-3282(95)00308-z
复制
发表时间：
1995
期刊：
影响因子：
4.1
通讯作者：
Chow,SY
中科院分区：
文献类型：
--
作者：
Jee,WS;Ma,YF;Chow,SY
由于持续治疗骨质疏松症的费用可能很高，而且可能会产生有害的影响，因此有必要制定一种策略，在停止治疗后保持骨量。由雌激素和降钙素治疗和运动维持的骨骼，但由合成代谢药物引起的增加的骨骼在停止治疗后消失。为了避免这一缺陷，激活、恢复和维持(ARM)或丢失、恢复和维持(LRM)的概念、联合合成代谢药与抗吸收或抗激活剂的开/关给药以及两种方案的循环治疗已成功地应用于临床前研究中的“保本”(保骨)。某些骨质疏松药物停止治疗后骨消失的数据、其丢失机制和维持概念的发展以及随后的临床前研究表明，在骨质疏松症的治疗策略中没有必要进行昂贵的持续治疗。
Since continuous therapy for osteoporosis can be expensive and may have detrimental effects, there is a need to develop a strategy to maintain bone mass after withdrawal of treatment. The bone maintained by estrogen and calcitonin therapies and exercise, but the added bone induced by anabolic agents disappears upon cessation of treatment. To avoid this pitfall, the concepts of activation, restore and maintain (ARM) or loss, restore and maintain (LRM), the on/off administration of combined anabolic agent with an antiresorptive or antiactivation agent, and cyclical treatment of the two regimes have been employed successfully in “keeping the profit” (maintaining bone) in preclinical studies. The data for the disappearance of bone upon cessation of certain osteopenic treatments, its mechanism of loss and the development of maintenance concept and subsequent preclinical studies indicate that there was no need for costly continuous therapy in the treatment strategy for osteoporosis.